Trial Profile

A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NL 201 Neoleukin Therapeutics (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Renal cancer; Renal cell carcinoma; Skin cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Neoleukin Therapeutics; Neurogene Inc

Most Recent Events

07 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Aug 2024.
14 Nov 2022 According to a Neoleukin Therapeutics media release, the company has discontinue the drug development of NL-201.
14 Nov 2022 Status changed from recruiting to discontinued, according to a Neoleukin Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com